Infinity’s IPI-549 Gets Fast Track Tag for Urothelial Cancer

Shares of Infinity Pharmaceuticals, Inc. INFI were up 12% yesterday after the FDA granted a Fast Track designation to the combo of IPI-549 plus Bristol Myers’ BMY Opdivo (nivolumab) for the treatment of advanced urothelial cancer, a type of bladder cancer.